The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage

Thrombosis and Haemostasis

Volumn 77, Issue 3, 1997, Pages 540-547

  Wohn, Karl Dieter ^a   Kanse, Sandip M ^a   Deutsch, Varda ^b   Schmidt, Thomas ^a   Eldor, Amiram ^b   Preissner, Klaus T ^a  

^a KERCKHOFF HEART CENTER   (Germany)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; CELL SURFACE PROTEIN; FIBRINOGEN RECEPTOR; GLYCOLIPID; MESSENGER RNA; PHORBOL ESTER; PHOSPHOLIPASE C; PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BONE MARROW; CELL COMMUNICATION; CELL CULTURE; CELL DIFFERENTIATION; CELL INTERACTION; CELL MOTILITY; CELL SELECTION; CELL STIMULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LIGAND BINDING; MEGAKARYOBLAST; MEGAKARYOCYTE; MEGAKARYOPOIESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030969990     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656003     Document Type: Article

References (65)

1. Gewirtz AM, Schick B. Megakaryocytopoiesis. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. J. B. Lippincott Company, Philadelphia, PA 1994; pp 353-96.
2. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, Methia N, Breton-Gorius J, Cosman D, Vainchenker W. c-Mpl ligand is a humoral regulator of megakaryo-cytopoiesis. Nature 1994; 369: 571-4.
3. Avraham H, Ellis MH, Jhun BH, Rja S, Chalasani D, Avraham S. Tyrosine kinases in megakaryocytopoiesis. Stem Cells 1995; 13: 380-92.
4. Hoffman R. Regulation of megakaryocytopoiesis. Blood 1989; 74: 1196-212.
5. Brunner G, Preissner KT. Pericellular enyzmatic hydrolysis: implications for the regulation of cell proliferation in the vessel wall and the bone marrow. Blood Coagul Fibrinol 1994; 5: 625-39.
6. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-72.
7. Kramer MD, Schaefer B, Reinartz J. Plasminogen activation by human keratinocytes:Molecular pathways and cell-biological consequences. Biol Chem Hoppe Seyl 1995; 376: 131-41.
8. Danø K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
9. Vassalli J-D. The urokinase receptor. Fibrinolysis 1994; 8: 172-81.
10. Loskutoff DJ, Sawdey M, Mimuro J. Type-1 plasminogen-activator inhibitor. Prog Hemostas Thromb 1989; 9: 87-115.
11. Blasi F, Conese M, Moller LB, Pederson N, Cavallaro U, Cubellis MV, Fazioli F, Hernandez-Marrero L, Limpongi P, Munoz-Canoves P, Resnati M, Riittinen L, Sidenius N, Soravia E, Soria MR, Stoppelli MP, Talarico D, Teesalu T, Valcamonica S. The urokinase-recptor: structure, regulation and inhibitor-mediated internalization. Fibrinolysis 1994; 8: 182-8.
12. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor: protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994; 8: 189-203.
13. Nielsen LS, Kellerman GM, Behrendt N, Picone R, Danø K, Blasi F. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator: Identification in human tumor cell lines and partial purification. J Biol Chem 1988; 263: 2358-63.
14. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985; 82: 4939-43.
15. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86-92.
16. Plesner T, Ralfkiaer E, Wittrup M, Johnsen H, Pyke C, Pedersen TL, Hansen NE, Dano K. Expression of the receptor for urokinase-type plasminogen-activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 1994; 102: 83541.
17. Nykjaer A, Petersen CM, Moller B, Andreasen PA, Gliemann J. Identification and characterization of urokinase receptors in natural killer cells and T-cell-derived lymphokine-activated killer cells. FEBS Lett 1992; 300: 13-7.
18. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule for cell surface plasmin dependent proteolysis. EMBO J 1990; 9: 467-74.
19. Min HY, Semnani R, Mizukami IF, Watt K, Todd III RF, Liu DY. cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. J Immunol 1992; 148: 3636-42.
20. Lund LR, Romer J, Ronne E, Ellis V, Blasi F, Dano K. Urokinase-receptor bio-synthesis, messenger-RNA level and gene transcription are increased by transforming growth factor 1 in human A549 lung-carcinoma cells. EMBO J 1991; 10: 3399-407.
21. Lund LR, Ronne E, Roldan AL, Behrendt N, Romer J, Blasi F, Dano K. Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. J Biol Chem 1991; 266: 5177-81.
22. Jeanneau C, Sultan Y. Tissue-plasminogen activator in human megakaryocytes and platelets: Immunocytochemical localization, immunoblotting and zymographic analysis. Thromb Haemost 1988; 59: 529-34.
23. Alessi MC, Chomiki N, Berthier R, Schweitzer A, Fossat C, Juhan-Vague I. Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization. Thromb Haemost 1994; 72: 931-6.
24. Waltz DA, Sailor LZ, Chapman HA. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J Clin Invest 1993; 91: 1541-52.
25. Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, Dano K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992; 267: 18224-9.
26. Deutsch DG, Mertz ET. Plasminogen: Purification from human plasma by affinity chromatography. Science 1970; 170: 1095-6.
27. Preissner KT. Specific binding of plasminogen to vitronectin. Evidence for a modulatory role of vitronectin on fibrin(ogen)-induced plasmin formation by tissue plasminogen activator. Biochem Biophys Res Commun 1990; 168: 966-71.
28. Wilhelm O, Weidle U, Hohl S, Rettenberger P, Schmitt M, Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 1994; 337: 131-4.
29. Ogura M, Morishima Y, Ohno R, Kato Y, Hirabayashi N, Nagura H, Saito H. Establishment of a novel human megakaryocytic leukemia cell line MEG-01 with Philadelphia chromosome. Blood 1985; 66: 1384-92.
30. Greenberg SM, Rosenthal DS, Greeley TA, Tantravahi R, Handin RI. Characterization of a new megakaryoblastic cell line: the DAMI cell. Blood 1988; 72: 1968-76.
31. Fugman DA, Witte DP, Jones CL, Aronow BJ, Lieberman MA. In vitro establishment and characterization of a human megakaryoblastic cell line. Blood 1990; 75: 1252-63.
32. Edgell C-JS, McDonald GC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 1988; 80: 3734-7.
33. Beretz A, Freyssinet J-M, Gauchy J, Schmitt DA, Klein-Soyer C, Edgell S, Cazenave J-P. Stability of the thrombin-thrombomodulin complex on the surface of endothelial cells from human saphenous vein or from the cell line EA.hy 926. Biochem J 1989; 259: 35-40.
34. Stockmann A, Hess S, Declerck P, Timpl R, Preissner KT. Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem 1993; 268: 22874-82.
35. Preissner KT, Anders E, Grulich-Henn J, Müller-Berghaus G. Attachment of cultured human endothelial cells is promoted by specific association with S protein (vitronectin) as well as with the ternary S protein-thrombin-anti-thrombin III complex. Blood 1988; 71: 1581-9.
36. Laemmli UK. Cleavage of structure proteins during assembly of the head bacteriophage T4. Nature 1970; 227: 680-5.
37. Preissner KT, Holzhüter S, Justus C, Müller-Berghaus G. Identification and partial characterization of platelet vitronectin: Evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 1989; 74: 1989-96.
38. Wun TC, Kretzmer KK. cDNA cloning and expression in E.coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by HepG2 hepatoma cell. FEBS Lett 1987; 210: 11-6.
39. Haendler B, Hofer-Warbinek R, Hofer E. Complementary DNA for human T-cell cyclophilin. EMBO J 1987; 6: 947-50.
40. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-8.
41. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin binding protein on endothelial cells. Exp Cell Res 1996; 224: 344-53.
42. Falcone DJ, McCaffrey TA, Mathew J, McAdam K, Borth W. THP-1 macrophage membrane-bound plasmin activity is upregulated by transforming growth factor-1 via increased expression of urokinase and the urokinase receptor. J Cell Physiol 1995; 164: 334-43.
43. Langer DJ, Kuo A, Kariko K, Ahuja M, Klugherz BD, Ivanics KM, Hoxie JA, Williams WV, Liang BT, Cines DB, Bamathan ES. Regulation of the endothelial cell urokinase-type plasminogen activator receptor. Evidence for cyclic AMP-dependent and protein kinase C-dependent pathways. Circ Res 1993; 72: 330-40.
44. Gruneiro AJ, Montesanti DP, Corasanti JG, Markus G. The induction of the plasminogen activator system during phorbol ester (PMA)-induced differentiation in HL-60 leukemic cells. Fibrinolysis 1995; 9: 71-8.
45. Behrendt N, Ronne E, Ploug M, Petri T, Lober D, Nielsen LS, Schleuning W-D, Blasi F, Appella E, Dano K. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990; 265: 6453-60.
46. Blasi F, Behrendt N, Cubellis MV, Ellis V, Lund LR, Masucci MT, Moller LB, Olson DP, Pedersen N, Ploug M, Ronne E, Dano K. The urokinase receptor and regulation of cell surface plasminogen activation. Cell Differ Dev 1990; 32: 247-54.
47. Behrendt N, Ronne E, Dano K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyl 1995; 376: 269-79.
48. Jiang Y, Pannell R, Liu J-N, Gurewich V. Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes. Blood 1996; 87: 2775-81.
49. Brunner G, Gabrilove J, Rifkin DB, Wilson EL. Phospholipase C release of basic fibroplast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol 1991; 114: 1275-83.
50. Metz CN, Brunner G, Choi-Muira NH, Nguyen H, Gabrilove J, Caras IW, Altszuler N, Rifkin DB, Wilson EL, Davitz MA. Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D. EMBO J 1994; 13: 1741-51.
51. Coller BS, Seligsohn U, West SM, Scudder LE, Norton KJ. Platelet fibrinogen and vitronectin in Glanzmann thrombasthenia: Evidence consistent with specific roles for glycoprotein IIb/IIIa and αvβ3 integrins in platelet protein trafficking. Blood 1991; 78: 2603-10.
52. Nykjaer A, Kjoller L, Cohen RL, Lawrence DA, Gliemann J, Andreasen PA. Both pro-uPA and uPA-PAI-1 complex bind to the α2-macroglobulin/receptor LDL receptor-related protein - evidence for multiple independent contacts between the ligands and receptor. Ann N Y Acad Sci 1994; 737: 483-5.
53. Leven RM, Yee T. Collagenase production by guinea pig megakaryocytes in vitro. Exp Haematol 1990; 18: 743-9.
54. Leven RM, Tablin F. Extracellular matrix stimulation of guinea pig megakaryocyte proplatelet formation in vitro is mediated through the vitronectin receptor. Exp Haematol 1992; 20: 1316-22.
55. Leven RM. Differential regulation of integrin-mediated proplatelet formation and megakaryocyte spreading. J Cell Physiol 1995; 163: 597-607.
56. Ossowski L, Clunie O, Masucci M, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1993; 115: 1107-12.
57. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994; 13: 3983-91.
58. Wilhelm O, Schmitt M, Höhl S, Senekowitsch R, Graeff H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995; 13: 296-302.
59. Hess S, Kanse SM, Kost C, Preissner KT. The versatility of adhesion receptor ligands in haemostasis: morpho-reglatory functions of vitronectin. Thromb Haemost 1995; 74: 258-65.
60. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis. FASEB J 1995; 9: 934-8.
61. Dewerchin M, Van Nuffelen A, Wallays G, Bouché A, Moons L, Carmeliet P, Mulligan RC, Collen D. Generation and characterization of urokinase receptor-deicient mice. J Clin Invest 1996; 97: 870-8.
62. Bugge TH, Flick MJ, Danton MJS, Daugherty CC, Romer J, Dano K, Carmeliet P, Collen D, Degen JL. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996; 93: 5899-904.
63. Ploug M, Plesner T, Ronne E, Ellis V, Hoyers-Hansen G, Hansen NE, Dano K. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 1992; 79: 1447-55.
64. Ronne E, Pappot H, Grondahl-Hansen J, Hoyer-Hansen G, Plesner T, Hansen NE, Dano K. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 89: 576-81.
65. Ware RE, Hall SE, Rosse WF. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med 1991; 325: 991-6.